Evaluation of the ecotoxicity of model nanoparticles.

R. Barrena,E. Casals,J. Colón,X. Font,Antoni Sánchez,V. Puntes

DOI: https://doi.org/10.1016/j.chemosphere.2009.01.078

IF: 8.8

2009-05-01

Chemosphere

Abstract:

What problem does this paper attempt to address?

Progress and perspectives of universal influenza vaccine

Xinci XIE,Lu LIU,Songhua YUAN,Xiaoyan ZHANG,Jianqing XU

2016-01-01

Abstract:Influenza virus infections are a major public health concern and cause significant morbidity and mortality worldwide . Prevention of influenza through vaccine development is the most effective management strategy ,but it is challenged by the evolution of influenza virus variants that could help viruses evade human immunity .Furthermore ,the licensed influenza vaccines only induce strain-specific immunity and cannot provide reliable protection against unexpected pandemics and epidemics caused by antigen drift or shift variants . Therefore , research and development of universal vaccines which induce broad-spectrum immune responses has become a hotspot .The discovery of broadly neutralizing antibodies has provided new insights into vaccine development for the past years ,and the lucubration of conserved antigenic regions and the study of cellular immunity and the optimization of vaccine immunization strategy also promote the development of universal influenza vaccine .This review summarizes the encouraging scientific advances in the field with a focus on novel epitope-based approaches in vaccine design .
Progress towards the Development of a Universal Influenza Vaccine

Wen-Chien Wang,Ekramy E. Sayedahmed,Suryaprakash Sambhara,Suresh K. Mittal

DOI: https://doi.org/10.3390/v14081684

2022-07-30

Viruses

Abstract:Influenza viruses are responsible for millions of cases globally and significantly threaten public health. Since pandemic and zoonotic influenza viruses have emerged in the last 20 years and some of the viruses have resulted in high mortality in humans, a universal influenza vaccine is needed to provide comprehensive protection against a wide range of influenza viruses. Current seasonal influenza vaccines provide strain-specific protection and are less effective against mismatched strains. The rapid antigenic drift and shift in influenza viruses resulted in time-consuming surveillance and uncertainty in the vaccine protection efficacy. Most recent universal influenza vaccine studies target the conserved antigen domains of the viral surface glycoproteins and internal proteins to provide broader protection. Following the development of advanced vaccine technologies, several innovative strategies and vaccine platforms are being explored to generate robust cross-protective immunity. This review provides the latest progress in the development of universal influenza vaccines.
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Caryn Myn Li Lim,Thamil Vaani Komarasamy,Nur Amelia Azreen Binti Adnan,Ammu Kutty Radhakrishnan,Vinod R. M. T. Balasubramaniam

DOI: https://doi.org/10.1111/irv.13276

2024-03-22

Influenza and Other Respiratory Viruses

Abstract:Every year, influenza virus infections cause significant morbidity and mortality worldwide. They pose a substantial burden of disease, in terms of not only health but also the economy. Owing to the ability of influenza viruses to continuously evolve, annual seasonal influenza vaccines are necessary as a prophylaxis. However, current influenza vaccines against seasonal strains have limited effectiveness and require yearly reformulation due to the virus undergoing antigenic drift or shift. Vaccine mismatches are common, conferring suboptimal protection against seasonal outbreaks, and the threat of the next pandemic continues to loom. Therefore, there is a great need to develop a universal influenza vaccine (UIV) capable of providing broad and durable protection against all influenza virus strains. In the quest to develop a UIV that would obviate the need for annual vaccination and formulation, a multitude of strategies is currently underway. Promising approaches include targeting the highly conserved epitopes of haemagglutinin (HA), neuraminidase (NA), M2 extracellular domain (M2e) and internal proteins of the influenza virus. The identification and characterization of broadly neutralizing antibodies (bnAbs) targeting conserved regions of the viral HA protein, in particular, have provided important insight into novel vaccine designs and platforms. This review discusses universal vaccine approaches presently under development, with an emphasis on those targeting the highly conserved stalk of the HA protein, recent technological advancements used and the future prospects of a UIV in terms of its advantages, developmental obstacles and potential shortcomings.

infectious diseases,virology
Progress on adenovirus-vectored universal influenza vaccines

Kui Xiang,Guan Ying,Zhou Yan,Yan Shanshan,Zhang Lei,Li Hongjun,Sun Maosheng

DOI: https://doi.org/10.1080/21645515.2015.1016674

Abstract:Influenza virus (IFV) infection causes serious health problems and heavy financial burdens each year worldwide. The classical inactivated influenza virus vaccine (IIVV) and live attenuated influenza vaccine (LAIV) must be updated regularly to match the new strains that evolve due to antigenic drift and antigenic shift. However, with the discovery of broadly neutralizing antibodies that recognize conserved antigens, and the CD8(+) T cell responses targeting viral internal proteins nucleoprotein (NP), matrix protein 1 (M1) and polymerase basic 1 (PB1), it is possible to develop a universal influenza vaccine based on the conserved hemagglutinin (HA) stem, NP, and matrix proteins. Recombinant adenovirus (rAd) is an ideal influenza vaccine vector because it has an ideal stability and safety profile, induces balanced humoral and cell-mediated immune responses due to activation of innate immunity, provides 'self-adjuvanting' activity, can mimic natural IFV infection, and confers seamless protection against mucosal pathogens. Moreover, this vector can be developed as a low-cost, rapid-response vaccine that can be quickly manufactured. Therefore, an adenovirus vector encoding conserved influenza antigens holds promise in the development of a universal influenza vaccine. This review will summarize the progress in adenovirus-vectored universal flu vaccines and discuss future novel approaches.
Research Progress in Broad Neutralizing Antibodies and Universal Vaccines Against Influenza A Virus

Feng Daobin,Liu Mingbin,Zhang Xiaoyan,Xu Jianqing

DOI: https://doi.org/10.3760/cma.j.issn.0254-5101.2018.010.011

2018-01-01

Abstract:Influenza vaccination is the most effective means to prevent and control influenza epi-demics, and the universal influenza vaccine which can induce broad and long-term protective effect is still in its infancy. Up to date, several broad neutralizing antibodies that can antagonize a variety of influenza A vi-ruses have been identified, and the crystal structure of the antibody and HA complex reveals at least three highly conserved epitopes. Deep insights into the molecular mechanism of the interactions between neutrali-zing antibodies and virus antigen can elicit a new strategy not only for rational design of universal influenza vaccines, but also for the development of antibody-based therapeutics against influenza virus. In this paper, advances in research of universal neutralizing antibodies and vaccines for Influenza A virus are reviewed.
Research and Development of Universal Influenza Vaccines.

Lanying Du,Yusen Zhou,Shibo Jiang

DOI: https://doi.org/10.1016/j.micinf.2010.01.001

IF: 9.57

2010-01-01

Microbes and Infection

Abstract:The continuous threat of influenza pandemics determines the urgency and necessity to develop safe and effective vaccines against divergent influenza viruses. This review describes the advancements in the research and development of universal influenza vaccines based on the relatively conserved sequences of M2e, HA, and other proteins of influenza viruses.
Flu Universal Vaccines: New Tricks on an Old Virus

Ruikun Du,Qinghua Cui,Lijun Rong

DOI: https://doi.org/10.1007/s12250-020-00283-6

2020-01-01

Abstract:Conventional influenza vaccines are based on predicting the circulating viruses year by year, conferring limited effectiveness since the antigenicity of vaccine strains does not always match the circulating viruses. This necessitates development of universal influenza vaccines that provide broader and lasting protection against pan-influenza viruses. The discovery of the highly conserved immunogens (epitopes) of influenza viruses provides attractive targets for universal vaccine design. Here we review the current understanding with broadly protective immunogens (epitopes) and discuss several important considerations to achieve the goal of universal influenza vaccines.
Suicidal risk in antidepressant drug trials.

R. Baldessarini,M. Pompili,L. Tondo

DOI: https://doi.org/10.1001/ARCHPSYC.63.3.246

2006-03-01

Archives of General Psychiatry

Abstract:
Development of universal influenza vaccines based on influenza virus M and NP genes

M. Zheng,J. Luo,Z. Chen

DOI: https://doi.org/10.1007/s15010-013-0546-4

2013-11-01

Infection

Abstract:PurposeVaccination is the safest and most effective measure against influenza virus infections. However, traditional influenza vaccines cannot respond effectively to an unforeseen epidemic or pandemic caused by a virus with antigenic drifts or antigenic shifts. Therefore, developing a universal influenza vaccine (UIV) that induces broad-spectrum and long-term immunity has become a major trend in influenza vaccine research and development.MethodsThis article reviews the development of UIVs based on these conserved influenza virus proteins.Results and ConclusionThe matrix protein (M1, M2) and nucleoprotein (NP) of influenza viruses have highly conserved sequences, and they become the major target antigens of current UIV studies.

infectious diseases
The race toward a universal influenza vaccine: Front runners and the future directions

Longbo Hu,Geqi Lao,Rui Liu,Jin Feng,Fei Long,Tao Peng

DOI: https://doi.org/10.1016/j.antiviral.2022.105505

IF: 7.6

2022-12-25

Antiviral Research

Abstract:Influenza virus is the pathogen of influenza (flu) and millions of people suffer from the infection worldwide, posing a significant health risk. The current influenza vaccines induce neutralizing antibodies against hemagglutinin (HA) to achieve strain-specific neutralization. The effectiveness of seasonal vaccines is usually low and unpredictable because of the antigenic variation and genetic plasticity of viruses, as well as the interference of preexisting immunity. A universal influenza vaccine is urgently needed to prevent a wide variety of influenza viruses. Nevertheless, reaching this difficult optimal goal requires a step-by-step approach. Innovative strategies and vaccine platforms are being developed in order to generate robust cross-protective immunity. In this review, we summarize candidate influenza vaccines that meet two criteria: first, they are designed to provide protection against multiple influenza viruses; second, they had passed regulatory evaluations and have entered various stages of clinical trials. We discuss these vaccine candidates based on the different vaccine-production platforms, with the focus on antigen selection, design, adjuvants, immunomodulators, and routes of vaccine delivery in the development of universal influenza vaccines.

pharmacology & pharmacy,virology
Advancements in the Development of Subunit Influenza Vaccines.

Naru Zhang,Bo-Jian Zheng,Lu,Yusen Zhou,Shibo Jiang,Lanying Du

DOI: https://doi.org/10.1016/j.micinf.2014.12.006

IF: 9.57

2014-01-01

Microbes and Infection

Abstract:The ongoing threat of influenza epidemics and pandemics has emphasized the importance of developing safe and effective vaccines against infections from divergent influenza viruses. In this review, we first introduce the structure and life cycle of influenza A viruses, describing major influenza A virus-caused pandemics. We then compare different types of influenza vaccines and discuss current advancements in the development of subunit influenza vaccines, particularly those based on nucleoprotein (NP), extracellular domain of matrix protein 2 (M2e) and hemagglutinin (HA) proteins. We also illustrate potential strategies for improving the efficacy of subunit influenza vaccines.
Towards a universal influenza vaccine: different approaches for one goal

Giuseppe A. Sautto,Greg A. Kirchenbaum,Ted M. Ross

DOI: https://doi.org/10.1186/s12985-017-0918-y

IF: 5.916

2018-01-19

Virology Journal

Abstract:Influenza virus infection is an ongoing health and economic burden causing epidemics with pandemic potential, affecting 5–30% of the global population annually, and is responsible for millions of hospitalizations and thousands of deaths each year. Annual influenza vaccination is the primary prophylactic countermeasure aimed at limiting influenza burden. However, the effectiveness of current influenza vaccines are limited because they only confer protective immunity when there is antigenic similarity between the selected vaccine strains and circulating influenza isolates. The major targets of the antibody response against influenza virus are the surface glycoprotein antigens hemagglutinin (HA) and neuraminidase (NA). Hypervariability of the amino acid sequences encoding HA and NA is largely responsible for epidemic and pandemic influenza outbreaks, and are the consequence of antigenic drift or shift, respectively. For this reason, if an antigenic mismatch exists between the current vaccine and circulating influenza isolates, vaccinated people may not be afforded complete protection. There is currently an unmet need to develop an effective “broadly-reactive” or “universal” influenza vaccine capable of conferring protection against both seasonal and newly emerging pre-pandemic strains. A number of novel influenza vaccine approaches are currently under evaluation. One approach is the elicitation of an immune response against the “Achille’s heel” of the virus, i.e. conserved viral proteins or protein regions shared amongst seasonal and pre-pandemic strains. Alternatively, other approaches aim toward eliciting a broader immune response capable of conferring protection against the diversity of currently circulating seasonal influenza strains.In this review, the most promising under-development universal vaccine approaches are discussed with an emphasis on those targeting the HA glycoprotein. In particular, their strengths and potential short-comings are discussed. Ultimately, the upcoming clinical evaluation of these universal vaccine approaches will be fundamental to determine their effectiveness against preventing influenza virus infection and/or reducing transmission and disease severity.

virology
Advances in Development and Application of Influenza Vaccines

Jidang Chen,Jiehuang Wang,Jipei Zhang,Hinh Ly

DOI: https://doi.org/10.3389/fimmu.2021.711997

2021-07-13

Abstract:Influenza A virus is one of the most important zoonotic pathogens that can cause severe symptoms and has the potential to cause high number of deaths and great economic loss. Vaccination is still the best option to prevent influenza virus infection. Different types of influenza vaccines, including live attenuated virus vaccines, inactivated whole virus vaccines, virosome vaccines, split-virion vaccines and subunit vaccines have been developed. However, they have several limitations, such as the relatively high manufacturing cost and long production time, moderate efficacy of some of the vaccines in certain populations, and lack of cross-reactivity. These are some of the problems that need to be solved. Here, we summarized recent advances in the development and application of different types of influenza vaccines, including the recent development of viral vectored influenza vaccines. We also described the construction of other vaccines that are based on recombinant influenza viruses as viral vectors. Information provided in this review article might lead to the development of safe and highly effective novel influenza vaccines.
Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions

Kuei-Ching Hsiung,Huan-Jung Chiang,Sebastian Reinig,Shin-Ru Shih

DOI: https://doi.org/10.3390/vaccines12121345

2024-11-29

Vaccines

Abstract:The development of vaccines against RNA viruses has undergone a rapid evolution in recent years, particularly driven by the COVID-19 pandemic. This review examines the key roles that RNA viruses, with their high mutation rates and zoonotic potential, play in fostering vaccine innovation. We also discuss both traditional and modern vaccine platforms and the impact of new technologies, such as artificial intelligence, on optimizing immunization strategies. This review evaluates various vaccine platforms, ranging from traditional approaches (inactivated and live-attenuated vaccines) to modern technologies (subunit vaccines, viral and bacterial vectors, nucleic acid vaccines such as mRNA and DNA, and phage-like particle vaccines). To illustrate these platforms' practical applications, we present case studies of vaccines developed for RNA viruses such as SARS-CoV-2, influenza, Zika, and dengue. Additionally, we assess the role of artificial intelligence in predicting viral mutations and enhancing vaccine design. The case studies underscore the successful application of RNA-based vaccines, particularly in the fight against COVID-19, which has saved millions of lives. Current clinical trials for influenza, Zika, and dengue vaccines continue to show promise, highlighting the growing efficacy and adaptability of these platforms. Furthermore, artificial intelligence is driving improvements in vaccine candidate optimization and providing predictive models for viral evolution, enhancing our ability to respond to future outbreaks. Advances in vaccine technology, such as the success of mRNA vaccines against SARS-CoV-2, highlight the potential of nucleic acid platforms in combating RNA viruses. Ongoing trials for influenza, Zika, and dengue demonstrate platform adaptability, while artificial intelligence enhances vaccine design by predicting viral mutations. Integrating these innovations with the One Health approach, which unites human, animal, and environmental health, is essential for strengthening global preparedness against future RNA virus threats.

immunology,medicine, research & experimental
Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

Mark B. Carascal,Rance Derrick N. Pavon,Windell L. Rivera

DOI: https://doi.org/10.3389/fimmu.2022.878943

IF: 7.3

2022-05-19

Frontiers in Immunology

Abstract:Flu, a viral infection caused by the influenza virus, is still a global public health concern with potential to cause seasonal epidemics and pandemics. Vaccination is considered the most effective protective strategy against the infection. However, given the high plasticity of the virus and the suboptimal immunogenicity of existing influenza vaccines, scientists are moving toward the development of universal vaccines. An important property of universal vaccines is their ability to induce heterosubtypic immunity, i.e., a wide immune response coverage toward different influenza subtypes. With the increasing number of studies and mounting evidence on the safety and efficacy of recombinant influenza vaccines (RIVs), they have been proposed as promising platforms for the development of universal vaccines. This review highlights the current progress and advances in the development of RIVs in the context of heterosubtypic immunity induction toward universal vaccine production. In particular, this review discussed existing knowledge on influenza and vaccine development, current hemagglutinin-based RIVs in the market and in the pipeline, other potential vaccine targets for RIVs (neuraminidase, matrix 1 and 2, nucleoprotein, polymerase acidic, and basic 1 and 2 antigens), and deantigenization process. This review also provided discussion points and future perspectives in looking at RIVs as potential universal vaccine candidates for influenza.

immunology
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

Cowling, Benjamin J.

DOI: https://doi.org/10.1007/s40265-024-02083-8

2024-08-22

Drugs

Abstract:At various times in recent decades, surges have occurred in optimism about the potential for universal influenza vaccines that provide strong, broad, and long-lasting protection and could substantially reduce the disease burden associated with seasonal influenza epidemics as well as the threat posed by pandemic influenza. Each year more than 500 million doses of seasonal influenza vaccine are administered around the world, with most doses being egg-grown inactivated subunit or split-virion vaccines. These vaccines tend to have moderate effectiveness against medically attended influenza for influenza A(H1N1) and influenza B, and somewhat lower for influenza A(H3N2) where differences between vaccine strains and circulating strains can occur more frequently due to antigenic drift and egg adaptations in the vaccine strains. Several enhanced influenza vaccine platforms have been developed including cell-grown antigen, the inclusion of adjuvants, or higher antigen doses, to improve immunogenicity and protection. During the COVID-19 pandemic there was unprecedented speed in development and roll-out of relatively new vaccine platforms, including mRNA vaccines and viral vector vaccines. These new platforms present opportunities to improve protection for influenza beyond existing products. Other approaches continue to be explored. Incremental improvements in influenza vaccine performance should be achievable in the short to medium term.

pharmacology & pharmacy,toxicology
Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

Nicholas C Wu,Ali H Ellebedy,Nicholas C. Wu,Ali H. Ellebedy

DOI: https://doi.org/10.1016/j.it.2023.11.001

IF: 19.709

2024-01-12

Trends in Immunology

Abstract:Current seasonal influenza vaccines, which mainly target hemagglutinin (HA), require annual updates due to the continuous antigenic drift of the influenza virus. Developing an influenza vaccine with increased breadth of protection will have significant public health benefits. The recent discovery of broadly protective antibodies to neuraminidase (NA) has provided important insights into developing a universal influenza vaccine, either by improving seasonal influenza vaccines or designing novel immunogens. However, further in-depth molecular characterizations of NA antibody responses are warranted to fully leverage broadly protective NA antibodies for influenza vaccine designs. Overall, we posit that focusing on NA for influenza vaccine development is synergistic with existing efforts targeting HA, and may represent a cost-effective approach to generating a broadly protective influenza vaccine.

immunology
Influenza vaccine: progress in a vaccine that elicits a broad immune response

Irina Isakova-Sivak,Ekaterina Stepanova,Daria Mezhenskaya,Victoria Matyushenko,Polina Prokopenko,Ivan Sychev,Pei-Fong Wong,Larisa Rudenko

DOI: https://doi.org/10.1080/14760584.2021.1964961

2021-08-17

Expert Review of Vaccines

Abstract:The licensed seasonal influenza vaccines predominantly induce neutralizing antibodies against immunodominant hypervariable epitopes of viral surface proteins, with limited protection against antigenically distant influenza viruses. Strategies have been developed to improve vaccines' performance in terms of broadly reactive and long-lasting immune response induction.We have summarized the advancements in the development of cross-protective influenza vaccines and discussed the challenges in evaluating them in preclinical and clinical trials. Here, the literature regarding the current stage of development of universal influenza vaccine candidates was reviewedAlthough various strategies aim to redirect adaptive immune responses from variable immunodominant to immunosubdominant antigens, more conserved epitopes are being investigated. Approaches that improve antibody responses to conserved B cell epitopes have increased the protective efficacy of vaccines within a subtype or phylogenetic group of influenza viruses. Vaccines that elicit significant levels of T cells recognizing highly conserved viral epitopes possess a high cross-protective potential and may cover most circulating influenza viruses. However, the development of T cell-based universal influenza vaccines is challenging owing to the diversity of MHCs in the population, unpredictable degree of immunodominance, lack of adequate animal models, and difficulty in establishing T cell immunity in humans.cHA: chimeric HA; HBc: hepatitis B virus core protein; HA: hemagglutinin; HLA: human leucocyte antigen; IIV: inactivated influenza vaccine; KLH: keyhole limpet hemocyanin; LAH: long alpha helix; LAIV: live attenuated influenza vaccine; M2e: extracellular domain of matrix 2 protein; MHC: major histocompatibility complex; mRNA: messenger ribonucleic acid; NA: neuraminidase; NS1: non-structural protein 1; qNIV: quadrivalent nanoparticle influenza vaccine; TRM: tissue-resident memory T cells; VE: vaccine effectiveness; VLP: virus-like particles; VSV: vesicular stomatitis virus

immunology
M2e-Based Universal Influenza A Vaccines

Lei Deng,Ki Cho,Walter Fiers,Xavier Saelens

DOI: https://doi.org/10.3390/vaccines3010105

2015-02-13

Vaccines

Abstract:The successful isolation of a human influenza virus in 1933 was soon followed by the first attempts to develop an influenza vaccine. Nowadays, vaccination is still the most effective method to prevent human influenza disease. However, licensed influenza vaccines offer protection against antigenically matching viruses, and the composition of these vaccines needs to be updated nearly every year. Vaccines that target conserved epitopes of influenza viruses would in principle not require such updating and would probably have a considerable positive impact on global human health in case of a pandemic outbreak. The extracellular domain of Matrix 2 (M2e) protein is an evolutionarily conserved region in influenza A viruses and a promising epitope for designing a universal influenza vaccine. Here we review the seminal and recent studies that focused on M2e as a vaccine antigen. We address the mechanism of action and the clinical development of M2e-vaccines. Finally, we try to foresee how M2e-based vaccines could be implemented clinically in the future.

immunology,medicine, research & experimental
Nucleic Acid Vaccines against SARS-CoV-2

Ying Liu,Qing Ye

DOI: https://doi.org/10.3390/vaccines10111849

2022-11-01

Vaccines

Abstract:The coronavirus disease 2019 (COVID-19) has spread worldwide and imposed a substantial burden on human health, the environment, and socioeconomic development, which has also accelerated the process of nucleic acid vaccine development and licensure. Nucleic acid vaccines are viral genetic sequence-based vaccines and third-generation vaccines after whole virus vaccines and recombinant subunit vaccines, including DNA vaccines and RNA vaccines. They have many unique advantages, but there are many aspects that require optimization. Therefore, the purpose of this review is to discuss the research and development processes of nucleic acid vaccines, summarize the advantages and shortcomings, and propose further optimization strategies by taking COVID-19 vaccines as an example. Hopefully, this work can make a modest contribution in promoting the construction of emergency nucleic acid vaccine platforms and in avoiding the reemergence of similar public health emergencies.

immunology,medicine, research & experimental

Evaluation of the ecotoxicity of model nanoparticles.

Progress and perspectives of universal influenza vaccine

Progress towards the Development of a Universal Influenza Vaccine

Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines

Progress on adenovirus-vectored universal influenza vaccines

Research Progress in Broad Neutralizing Antibodies and Universal Vaccines Against Influenza A Virus

Research and Development of Universal Influenza Vaccines.

Flu Universal Vaccines: New Tricks on an Old Virus

Suicidal risk in antidepressant drug trials.

Development of universal influenza vaccines based on influenza virus M and NP genes

The race toward a universal influenza vaccine: Front runners and the future directions

Advancements in the Development of Subunit Influenza Vaccines.

Towards a universal influenza vaccine: different approaches for one goal

Advances in Development and Application of Influenza Vaccines

Vaccine Strategies Against RNA Viruses: Current Advances and Future Directions

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine

Targeting neuraminidase: the next frontier for broadly protective influenza vaccines

Influenza vaccine: progress in a vaccine that elicits a broad immune response

M2e-Based Universal Influenza A Vaccines

Nucleic Acid Vaccines against SARS-CoV-2